ATE534751T1 - Verwendung von prkx zur diagnose und therapie von alzheimer krankheit - Google Patents
Verwendung von prkx zur diagnose und therapie von alzheimer krankheitInfo
- Publication number
- ATE534751T1 ATE534751T1 AT06763387T AT06763387T ATE534751T1 AT E534751 T1 ATE534751 T1 AT E534751T1 AT 06763387 T AT06763387 T AT 06763387T AT 06763387 T AT06763387 T AT 06763387T AT E534751 T1 ATE534751 T1 AT E534751T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- alzheimer
- prkx
- diagnosing
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05104631 | 2005-05-30 | ||
| US68552505P | 2005-05-31 | 2005-05-31 | |
| PCT/EP2006/062741 WO2006128879A1 (en) | 2005-05-30 | 2006-05-30 | Diagnostic and therapeutic target prkx proteins for neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE534751T1 true ATE534751T1 (de) | 2011-12-15 |
Family
ID=35515928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06763387T ATE534751T1 (de) | 2005-05-30 | 2006-05-30 | Verwendung von prkx zur diagnose und therapie von alzheimer krankheit |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US8114620B2 (de) |
| EP (1) | EP1885886B1 (de) |
| JP (1) | JP4929277B2 (de) |
| AT (1) | ATE534751T1 (de) |
| WO (1) | WO2006128879A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2243830A4 (de) * | 2008-02-12 | 2011-10-26 | Takeda Pharmaceutical | Screening-verfahren |
| HUP0900431A2 (en) * | 2009-07-10 | 2011-01-28 | Cryo Innovation Kft | Sample imaging system and pocedure for transmitting imager of cells or tissues located in breeder space towards a data processing device |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4438391C2 (de) | 1994-10-27 | 1997-07-03 | Evotec Biosystems Gmbh | Vorrichtung zur Bestimmung stoffspezifischer Parameter eines oder weniger Moleküle mittels Korrelations-Spektroskopie |
| DE19709348C2 (de) | 1996-05-29 | 1999-07-01 | Schubert Walter Dr Md | Automatisches Multi-Epitop-Ligand-Kartierungsverfahren |
| EP0836090A1 (de) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Probenanalyseverfahren durch Bestimmung der spezifischen Helligkeitsverteilung von Teilchen |
| DE19649048C1 (de) | 1996-11-27 | 1998-04-09 | Evotec Biosystems Gmbh | Verfahren zur Unterscheidung oder Erfassung von Partikeln in einer Probe durch Identifizierung von Signalabschnitten zeitaufgelöster, optischer Rohsignale aus der Probe auf Basis von Einzelphotonendetektion |
| EP0945718A1 (de) | 1998-03-21 | 1999-09-29 | Evotec BioSystems AG | Ein Verfahren zur Probencharakterisierung durch Bestimmung einer Funktion mindestens einer spezifischen Eigenschaft von Einheiten der Probe |
| ATE208037T1 (de) | 1997-12-23 | 2001-11-15 | Evotec Biosystems Ag | Verfahren zum nachweis von reaktionen mittels koinzidenzanalyse |
| US20050123938A1 (en) | 1999-01-06 | 2005-06-09 | Chondrogene Limited | Method for the detection of osteoarthritis related gene transcripts in blood |
| EP1157267B1 (de) | 1999-03-03 | 2016-10-05 | Olympus Corporation | Fluoreszenz-assay-verfahren |
| JP3559525B2 (ja) | 1999-04-29 | 2004-09-02 | エボテック オーアーイー アクチェンゲゼルシャフト | 生成関数を用いて蛍光分子又は他の粒子を特徴付ける方法 |
| US6690463B2 (en) | 2000-02-10 | 2004-02-10 | Evotec Biosystems Ag | Fluorescence intensity and lifetime distribution analysis |
| DE60102797T2 (de) | 2000-02-10 | 2005-09-08 | Evotec Oai Ag | Fluoreszenzintensitätsanalyse unter verwendung einer vielzahl von verteilungen: konkurrierende bestimmung von diffusionszeiten und molekularer helligkeit |
| DE10030798A1 (de) | 2000-06-29 | 2002-01-10 | Evotec Analytical Sys Gmbh | Kompetitives Assay-Verfahren |
| US6916643B2 (en) * | 2002-05-06 | 2005-07-12 | Applera Corporation | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| EP1532276A2 (de) * | 2002-08-28 | 2005-05-25 | EVOTEC Neurosciences GmbH | Diagnostische und therapeutische verwendung von foap-13 polynukleotiden und polypeptiden für neurodegenerative erkrankungen |
| WO2005119262A2 (en) * | 2004-05-27 | 2005-12-15 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
-
2006
- 2006-05-30 WO PCT/EP2006/062741 patent/WO2006128879A1/en active Application Filing
- 2006-05-30 JP JP2008514099A patent/JP4929277B2/ja not_active Expired - Fee Related
- 2006-05-30 US US11/921,225 patent/US8114620B2/en not_active Expired - Fee Related
- 2006-05-30 EP EP06763387A patent/EP1885886B1/de not_active Not-in-force
- 2006-05-30 AT AT06763387T patent/ATE534751T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| US8114620B2 (en) | 2012-02-14 |
| JP4929277B2 (ja) | 2012-05-09 |
| US20090136504A1 (en) | 2009-05-28 |
| EP1885886B1 (de) | 2011-11-23 |
| JP2008545423A (ja) | 2008-12-18 |
| WO2006128879A1 (en) | 2006-12-07 |
| EP1885886A1 (de) | 2008-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE530667T1 (de) | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit | |
| WO2005108999A3 (en) | Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease | |
| ATE461941T1 (de) | Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation | |
| EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
| ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| DK2172208T3 (da) | Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser | |
| WO2004070388A8 (en) | Diagnostic and therapeutic use of scn2b protein for neurodegenerative diseases | |
| ATE495269T1 (de) | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen | |
| ATE534751T1 (de) | Verwendung von prkx zur diagnose und therapie von alzheimer krankheit | |
| WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
| WO2004003563A3 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
| ATE458834T1 (de) | Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten | |
| ATE465408T1 (de) | Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins | |
| ATE464567T1 (de) | Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen | |
| WO2005030947A3 (en) | Diagnostic and therapeutic use of a sulfotransferase for neurodegenerative diseases | |
| WO2005101014A3 (en) | Diagnostic and therapeutic use of kcnc1 for neurodegenerative diseases | |
| WO2005059562A3 (en) | Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases | |
| WO2006131562A3 (en) | Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases | |
| ATE316657T1 (de) | Diagnostische und therapeutische verwendung des caps | |
| WO2004020665A3 (en) | Diagnostic and therapeutic use of foap-13 polynucleotides and polypeptides for neurodegenerative diseases | |
| ATE365175T1 (de) | Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten | |
| DE60227650D1 (de) | Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer-krankheit und relatierte neurodegeneratiefe störungen | |
| WO2006008294A3 (en) | Diagnostic and therapeutic use of slim3 for neurodegenerative diseases | |
| WO2003104811A3 (en) | DIAGNOSTIC AND THERAPEUTIC USE OF THE ACUTE STEROIDOGEN RESPONSE REGULATORY PROTEIN FOR TREATING NEURODEGENERATIVE DISEASES | |
| WO2003085131A3 (en) | Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases |